Discovery of early urinary biomarkers in preclinical study of gentamicin-induced kidney injury and recovery in rats

Metabolomics

Volumn 8, Issue 6, 2012, Pages 1181-1193

  Sun, Jinchun ^a   Bhattacharyya, Sudeepa ^b   Schnackenberg, Laura K ^a   Pence, Lisa ^a   Ando, Yosuke ^c   Zhang, Jun ^d   Stewart, Sharon ^d   Rosenzweig, Barry ^d   Rouse, Rodney ^d   Portilla, Didier ^e   Beger, Richard D ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c DAIICHI SANKYO CO   (Japan)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Biomarker; Dopamine; Efficacy; Gentamicin; Metabolomics; Nephrotoxicity

Indexed keywords

BIOLOGICAL MARKER; CREATININE; DOPAMINE; GENTAMICIN; HOMOVANILLIC ACID SULFATE; HOMOVERATRIC ACID SULFATE; HYDROXYPROLINE; NITROGEN; SULFATE; TYROSINE; UNCLASSIFIED DRUG; UREA; VALINE;

AMINO ACID ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; GLUCOSURIA; HISTOPATHOLOGY; INTESTINE FLORA; KIDNEY INJURY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PREDICTION; RAT; SENSITIVITY ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE LEVEL;

ANIMALIA; RATTUS;

EID: 84868372491     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-012-0423-7     Document Type: Article

References (42)

1. Arzuaga, X., Rieth, S. H., Bathija, A., & Cooper, G. S. (2010). Renal effects of exposure to natural and depleted uranium: a review of the epidemiologic and experimental data. Journal of Toxicology and Environmental Health Part B, 13, 527-545.
2. Beger, R. D., Holland, R. D., Sun, J., Schnackenberg, L. K., Moore, P. C., Dent, C. L., et al. (2008). Metabonomics of acute kidney injury in children after cardiac surgery. Pediatric Nephrology (Berlin, Germany), 23, 977-984.
3. Bennett, W. M., Mela-Riker, L. M., Houghton, D. C., Gilbert, D. N., & Buss, W. C. (1988). Microsomal protein synthesis inhibition: An early manifestation of gentamicin nephrotoxicity. American Journal of Physiology, 255, F265-F269.
4. Bone, E., Tamm, A., & Hill, M. (1976). The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. American Journal of Clinical Nutrition, 29, 1448-1454.
5. Boudonck, K. J., Mitchell, M. W., Német, L., Keresztes, L., Nyska, A., Shinar, D., et al. (2009). Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicologic Pathology, 37, 280-292.
6. Conger, J. D., Falk, S. A., & Hammond, W. S. (1991). Atrial natriuretic peptide and dopamine in established acute renal failure in the rat. Kidney International, 40, 21-28.
7. Davis, J. W., & Kramer, J. A. (2006). Genomic-based biomarkers of drug-induced nephrotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2, 95-101.
8. Dieterle, F., Sistare, F., Goodsaid, F., Papaluca, M., Ozer, J. S., Webb, C. P., et al. (2010). Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature Biotechnology, 28, 455-462.
9. Duarte, C. G., & Preuss, H. G. (1993). Assessment of renal function-glomerular and tubular. Clinics in Laboratory Medicine, 13, 33-52.
10. Emeigh, S., & Kinter, L. (2005). Assessing renal effects of toxicants in vitro. In J. Tarloff & L. Lash (Eds.), Toxicology of the kidney (3rd ed., pp. 81-147). Washington, DC: CRC Press.
11. Espandiari, P., Zhang, J., Rosenzweig, B. A., Vaidya, V. S., Sun, J., Schnackenberg, L. K., et al. (2007). The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicological Sciences, 99, 637-648.
12. Espandiari, P., Zhang, J., Schnackenberg, L. K., Miller, T. J., Knapton, A., Herman, E. H., et al. (2008). Age-related differences in susceptibility to toxic effects of valproic acid in rats. Journal of Applied Toxicology, 28, 628-637.
13. Faiz, H., Conjard-Duplany, A., Boghossian, M., Martin, G., Baverel, G., & Ferrier, B. (2011). Cadmium chloride inhibits lactate gluconeogenesis in isolated human renal proximal tubules: A cellular metabolomic approach with (13)C-NMR. Archives of Toxicology, 85, 1067-1077.
14. Gare, M., Haviv, Y. S., Ben-Yehuda, A., Rubinger, D., Bdolah-Abram, T., Fuchs, S., et al. (1999). The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. Journal of the American College of Cardiology, 34, 1682-1688.
15. Goodsaid, F., & Frueh, F. W. (2007). Biomarker qualification pilot process at the US Food and Drug Administration. AAPS Journal, 9, E105-E108.
16. Goodsaid, F. M., Frueh, F. W., & Mattes, W. (2008). Strategic paths for biomarker qualification. Toxicology, 245, 219-223.
17. Jernberg, C., Löfmark, S., Edlund, C., & Jansson, J. K. (2007). Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME Journal, 1, 56-66.
18. 1H NMR) in rats. Toxicology and Applied Pharmacology, 249, 114-126.
19. Lee, M. R. (1993). Dopamine and the kidney: Ten years on. Clinical Science, 84, 357-375.
20. Lenz, E. M., Bright, J., Knight, R., Wilson, I. D., & Major, H. (2004a). Cyclosporin A-induced changes in endogenous metabolites in rat urine: A metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. Journal of Pharmaceutical and Biomedical Analysis, 35, 599-608.
21. Lenz, E. M., Bright, J., Knight, R., Wilson, I. D., & Major, H. (2004b). A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: Time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst, 129, 535-541.
22. Lenz, E. M., Bright, J., Knight, R., Westwood, F. R., Davies, D., Major, H., et al. (2005). Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers, 10, 173-187.
23. Ling, X. B., Sigdel, T. K., Lau, K., Ying, L., Lau, I., Schilling, J., et al. (2010). Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. Journal of the American Society of Nephrology, 21, 646-653.
24. Lv, H., Liu, L., Zhang, Y., Song, T., Lu, J., & Chen, X. (2010). Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Molecular Biosystems, 6, 2056-2067.
25. Macpherson, N. A., Moscarello, M. A., & Goldberg, D. M. (1991). Aminoaciduria is an earlier index of renal tubular damage than conventional renal disease markers in the gentamicin-rat model of acute renal failure. Clinical and Investigative Medicine, 14, 101-110.
26. Mitsui, G., Dote, T., Yamadori, E., Imanishi, M., Nakayama, S., Ohnishi, K., et al. (2010). Toxicokinetics and metabolism deteriorated by acute nephrotoxicity after a single intravenous injection of hydrofluoric acid in rats. Journal of Occupational Health, 52, 395-399.
27. Nicholson, J. K., Holmes, E., & Wilson, I. D. (2005). Gut microorganisms, mammalian metabolism and personalized health care. Nature Reviews Microbiology, 3, 431-438.
28. Portilla, D., Li, S., Nagothu, K. K., Megyesi, J., Kaissling, B., Schnackenberg, L. K., et al. (2006). Metabolomic study of cisplatin-induced nephrotoxicity. Kidney International, 69, 2194-2204.
29. Price, R. G. (1992). The role of NAG (N-acetyl-beta-d-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clinical Nephrology, 38, S14-S19.
30. Rouse, R. L., Zhang, J., Stewart, S. R., Rosenzweig, B. A., Espandiari, P., & Sadrieh, N. K. (2011). Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney International, 79, 1186-1197.
31. Sangster, T., Major, H., Plumb, R., Wilson, A. J., & Wilson, I. D. (2006). A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst, 131, 1075-1078.
32. Shimada, M., Terazawa, R., Kamiyama, Y., Honma, W., Nagata, K., & Yamazoe, Y. (2004). Unique properties of a renal sulfotransferase, St1d1, in dopamine metabolism. Journal of Pharmacology and Experimental Therapeutics, 310, 808-814.
33. Smith, E. A., & Macfarlane, G. T. (1996). Enumeration of human colonic bacteria producing phenolic and indolic compounds: Effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. Journal of Applied Bacteriology, 81, 288-302.
34. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R., & Siuzdak, G. (2006). XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Analytical Chemistry, 78, 779-787.
35. Tayebati, S. K., Lokhandwala, M. F., & Amenta, F. (2011). Dopamine and vascular dynamics control: Present status and future perspectives. Current Neurovascular Research, 8, 246-257.
36. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444, 1027-1031.
37. Turnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008). Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host and Microbe, 17, 213-223.
38. van de Poll, M. C., Soeters, P. B., Deutz, N. E., Fearon, K. C., & Dejong, C. H. (2004). Renal metabolism of amino acids: Its role in interorgan amino acid exchange. American Journal of Clinical Nutrition, 79, 185-197.
39. Werner, M., Costa, M. J., Mitchell, L. G., & Nayar, R. (1995). Nephrotoxicity of xenobiotics. Clinica Chimica Acta, 237, 107-154.
40. Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., et al. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of the National Academy of Sciences of USA, 106, 3698-3703.
41. Wolfovitz, E., Grossman, E., Folio, C. J., Keiser, H. R., Kopin, I. J., & Goldstein, D. S. (1993). Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans. Clinical Science, 84, 549-557.
42. Zhang, J., Goering, P. G., Espandiari, P., Shaw, M., Bonventre, J. V., Vaidya, V. S., et al. (2009). Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: Potential role of iNOS and nitrotyrosine. Toxicologic Pathology, 37, 629-643.